The Discovery of Phthalazinone-Based Human H1and H3Single-Ligand Antagonists Suitable for Intranasal Administration for the Treatment of Allergic Rhinitis
Citations Over TimeTop 14% of 2011 papers
Abstract
A series of potent phthalazinone-based human H(1) and H(3) bivalent histamine receptor antagonists, suitable for intranasal administration for the potential treatment of allergic rhinitis, were identified. Blockade of H(3) receptors is thought to improve efficacy on nasal congestion, a symptom of allergic rhinitis that is currently not treated by current antihistamines. Two analogues (56a and 56b) had slightly lower H(1) potency (pA(2) 9.1 and 8.9, respectively, vs 9.7 for the clinical gold-standard azelastine, and H(3) potency (pK(i) 9.6 and 9.5, respectively, vs 6.8 for azelastine). Compound 56a had longer duration of action than azelastine, low brain penetration, and low oral bioavailability, which coupled with the predicted low clinical dose, should limit the potential of engaging CNS-related side-effects associated with H(1) or H(3) antagonism.
Related Papers
- → Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis(2006)77 cited
- → Effect of topical nasal azelastine on the symptoms of rhinitis, sleep, and daytime somnolence in perennial allergic rhinitis(2000)46 cited
- → Intranasal phototherapy versus azelastine in the treatment of seasonal allergic rhinitis(2012)14 cited
- → Efficacy and safety of azelastine nasal spray for the treatment of allergic rhinitis(1999)17 cited
- → Allergic rhinitis: the choice of rational treatment(2017)